Aljian Capital Management LLC Makes New $27,000 Investment in Femasys Inc. (NASDAQ:FEMY)

Aljian Capital Management LLC bought a new stake in shares of Femasys Inc. (NASDAQ:FEMY) in the third quarter, Holdings Channel reports. The fund bought 24,768 shares of the company’s stock, valued at approximately $27,000.

Separately, CM Management LLC lifted its holdings in Femasys by 6.3% during the second quarter. CM Management LLC now owns 425,000 shares of the company’s stock valued at $484,000 after purchasing an additional 25,000 shares during the last quarter. Institutional investors own 65.27% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Chardan Capital reduced their target price on shares of Femasys from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Femasys in a report on Tuesday, November 12th.

Femasys Stock Performance

Shares of FEMY opened at $0.93 on Tuesday. Femasys Inc. has a 52-week low of $0.73 and a 52-week high of $2.40. The stock’s 50-day simple moving average is $1.15 and its 200 day simple moving average is $1.14. The company has a debt-to-equity ratio of 0.86, a quick ratio of 5.93 and a current ratio of 3.94. The stock has a market capitalization of $21.34 million, a price-to-earnings ratio of -1.15 and a beta of -2.83.

Femasys (NASDAQ:FEMY) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). The firm had revenue of $0.55 million during the quarter, compared to analysts’ expectations of $0.40 million. Femasys had a negative return on equity of 141.49% and a negative net margin of 1,435.77%. Research analysts forecast that Femasys Inc. will post -0.84 EPS for the current fiscal year.

Femasys Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.